Provectus Biopharmaceuticals Stock Earnings Per Share
PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceuticals fundamentals help investors to digest information that contributes to Provectus Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Provectus OTC Stock. The fundamental analysis module provides a way to measure Provectus Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Provectus Biopharmaceutica otc stock.
Provectus |
Provectus Biopharmaceuticals OTC Stock Earnings Per Share Analysis
Provectus Biopharmaceutica's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Provectus Biopharmaceutica Earnings Per Share | (0.01) X |
Most of Provectus Biopharmaceutica's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Provectus Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Provectus Biopharmaceuticals has an Earnings Per Share of -0.012 times. This is 100.14% lower than that of the Pharmaceuticals sector and 99.75% lower than that of the Health Care industry. The earnings per share for all United States stocks is 100.38% higher than that of the company.
Provectus Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provectus Biopharmaceutica's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Provectus Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics of similar companies.Provectus Biopharmaceutica is currently under evaluation in earnings per share category among its peers.
Provectus Fundamentals
Return On Asset | -1.85 | ||||
Operating Margin | (4.77) % | ||||
Current Valuation | 46.73 M | ||||
Shares Outstanding | 419.55 M | ||||
Shares Owned By Insiders | 3.69 % | ||||
Shares Owned By Institutions | 0.04 % | ||||
Number Of Shares Shorted | 1.82 M | ||||
Price To Earning | (0.48) X | ||||
Price To Book | 5.44 X | ||||
Price To Sales | 55.94 X | ||||
EBITDA | (4.56 M) | ||||
Net Income | (5.54 M) | ||||
Cash And Equivalents | 84.27 K | ||||
Total Debt | 2.29 M | ||||
Debt To Equity | 0.25 % | ||||
Current Ratio | 0.27 X | ||||
Book Value Per Share | (0.02) X | ||||
Cash Flow From Operations | (1.01 M) | ||||
Short Ratio | 0.47 X | ||||
Earnings Per Share | (0.01) X | ||||
Target Price | 3.5 | ||||
Beta | 0.5 | ||||
Market Capitalization | 44.47 M | ||||
Total Asset | 3.51 M | ||||
Retained Earnings | (180.8 M) | ||||
Working Capital | 10.6 M | ||||
Current Asset | 14.72 M | ||||
Current Liabilities | 4.12 M | ||||
Z Score | -59.7 | ||||
Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |